tetano
Editor, Senior Moderator
J Clin Virol
. 2021 Jul 7;142:104907.
doi: 10.1016/j.jcv.2021.104907. Online ahead of print.
A second external quality assessment of isolation and identification of influenza viruses in cell culture in the Asia Pacific region highlights improved performance by participating laboratories
Vivian K Y Leung[SUP] 1 [/SUP], Yi-Mo Deng[SUP] 1 [/SUP], Angela Todd[SUP] 1 [/SUP], Heidi Peck[SUP] 1 [/SUP], Iwona Buettner[SUP] 1 [/SUP], Tasoula Zakis[SUP] 1 [/SUP], Kanta Subbarao[SUP] 1 [/SUP], Ian G Barr[SUP] 1 [/SUP], Karen Nahapetyan[SUP] 2 [/SUP], Francis Y Inbanathan[SUP] 3 [/SUP], Magdi Samaan[SUP] 4 [/SUP], Patrick C Reading[SUP] 5 [/SUP]
Affiliations
Abstract
Influenza viruses must be amplified in cell culture for detailed antigenic analysis and for phenotypic assays assessing susceptibility to antiviral drugs or for other assays. Following on from the first external quality assessment (EQA) for isolation and identification of influenza viruses using cell culture techniques in 2016, a follow up EQA was performed in 2019 for National Influenza Centres (NICs) in the World Health Organization (WHO) South East Asia and Western Pacific Regions. Nineteen WHO NICs performed influenza virus isolation and identification techniques on an EQA panel comprising 16 samples, containing influenza A or B viruses and negative control samples. One sample was used exclusively to assess capacity to measure a hemagglutination titer and the other 15 samples were used for virus isolation and subsequent identification. Virus isolation from EQA samples was generally detected by assessment of cytopathic effect and/or hemagglutination assay while virus identification was determined by real time RT-PCR, hemagglutination inhibition and/or immunofluorescence assays. For virus isolation from EQA samples, 6/19 participating laboratories obtained 15/15 correct results in the first EQA (2016) compared to 11/19 in the follow up (2019). For virus identification in isolates derived from EQA samples, 6/19 laboratories obtained 15/15 correct results in 2016 compared to 13/19 in 2019. Overall, NIC laboratories in the Asia Pacific Region showed a significant improvement between 2016 and 2019 in terms of the correct results reported for isolation from EQA samples and identification of virus in isolates derived from EQA samples (p=0.01 and p=0.02, respectively).
Keywords: External quality assessment; Influenza; Virus isolation.
. 2021 Jul 7;142:104907.
doi: 10.1016/j.jcv.2021.104907. Online ahead of print.
A second external quality assessment of isolation and identification of influenza viruses in cell culture in the Asia Pacific region highlights improved performance by participating laboratories
Vivian K Y Leung[SUP] 1 [/SUP], Yi-Mo Deng[SUP] 1 [/SUP], Angela Todd[SUP] 1 [/SUP], Heidi Peck[SUP] 1 [/SUP], Iwona Buettner[SUP] 1 [/SUP], Tasoula Zakis[SUP] 1 [/SUP], Kanta Subbarao[SUP] 1 [/SUP], Ian G Barr[SUP] 1 [/SUP], Karen Nahapetyan[SUP] 2 [/SUP], Francis Y Inbanathan[SUP] 3 [/SUP], Magdi Samaan[SUP] 4 [/SUP], Patrick C Reading[SUP] 5 [/SUP]
Affiliations
- PMID: 34274614
- DOI: 10.1016/j.jcv.2021.104907
Abstract
Influenza viruses must be amplified in cell culture for detailed antigenic analysis and for phenotypic assays assessing susceptibility to antiviral drugs or for other assays. Following on from the first external quality assessment (EQA) for isolation and identification of influenza viruses using cell culture techniques in 2016, a follow up EQA was performed in 2019 for National Influenza Centres (NICs) in the World Health Organization (WHO) South East Asia and Western Pacific Regions. Nineteen WHO NICs performed influenza virus isolation and identification techniques on an EQA panel comprising 16 samples, containing influenza A or B viruses and negative control samples. One sample was used exclusively to assess capacity to measure a hemagglutination titer and the other 15 samples were used for virus isolation and subsequent identification. Virus isolation from EQA samples was generally detected by assessment of cytopathic effect and/or hemagglutination assay while virus identification was determined by real time RT-PCR, hemagglutination inhibition and/or immunofluorescence assays. For virus isolation from EQA samples, 6/19 participating laboratories obtained 15/15 correct results in the first EQA (2016) compared to 11/19 in the follow up (2019). For virus identification in isolates derived from EQA samples, 6/19 laboratories obtained 15/15 correct results in 2016 compared to 13/19 in 2019. Overall, NIC laboratories in the Asia Pacific Region showed a significant improvement between 2016 and 2019 in terms of the correct results reported for isolation from EQA samples and identification of virus in isolates derived from EQA samples (p=0.01 and p=0.02, respectively).
Keywords: External quality assessment; Influenza; Virus isolation.